Melissa Ullerich compensation by year
SAB Biotherapeutics Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $256,196 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $870,751 |
| Non-equity incentive | $266,126 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $1,393,073 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed May 25, 2022, accession 0000950170-22-010672, and prior-year filings. Open the filing on EDGAR.
How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0000950170-22-010672. Every figure is read from that document and cited to the page and table it appears in. Filed May 25, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 43,621 | — | $4.04 |
Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
SAB Biotherapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Samuel Reich | Executive Chairman of the Board of Directors | $2,795,626 |
| Melissa Ullerich · this page | Former EVP, Chief of Corporate Communications, Investor Relations Officer (4) | $1,393,073 |
| Eddie Sullivan | President and Chief Executive Officer | $526,821 |
The full SAB Biotherapeutics compensation record
free company briefThis page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.